posted
You might be right. I've just never seen the point of hating shorters. If I'm right about a stock, and they're wrong, they lose money. If they're right, and I'm wrong, they lose money. Simple as that.
-------------------- "Entrepreneurship is the last refuge of the trouble making individual."
posted
I would tend to agree with you there. I don't know a WHOLE lot about naked shorting, but aren't they taking a HUGE risk if it moves to the upside?
-------------------- "Entrepreneurship is the last refuge of the trouble making individual."
posted
I see your point do you see mine I feel raped when people sell something I bought and they don't even own it they borrow from people who do own it and sell their shares it's like stealing my shares from my acct and selling them
IP: Logged |
quote:Originally posted by Kevin Bailey: I would tend to agree with you there. I don't know a WHOLE lot about naked shorting, but aren't they taking a HUGE risk if it moves to the upside?
Well, retail investors are, yes... however, if you're a hedge fund, and you are naked short and you have no intention to deliver the shares.. then no.
-------------------- Stick with Repo's plan in '07 - FRPT/DKAM!
IP: Logged |
quote:Originally posted by pick em low: I see your point do you see mine I feel raped when people sell something I bought and they don't even own it they borrow from people who do own it and sell their shares it's like stealing my shares from my acct and selling them
If you're talking about NAKED shorting, I would agree with you. Since you're not, I don't. When a stock is sold short it takes two parties to make the transaction work. It's no different AT ALL than betting on a stock's upward move. Shorts actually provide cushion for a drop, as they cover their positions as the stock falls, providing price support at various levels. If there's no short interest in a stock, when it plummets, it PLUMMETS! See Circuit City for an example. There was little or no short interest in the stock at the $24-25 level, and when bad news hit, it plunged to about $19, without a breather. Shorts give the falling stock "waystations" of a sort, as shorts cover their positions, taking their profits, and providing natural buyers at levels where buyers would otherwise not be.
-------------------- "Entrepreneurship is the last refuge of the trouble making individual."
posted
Did anyone pick up an JSDA when I mentioned in this thread Wednesday that I had sold it at $10.25? It got mentioned by Cramer yesterday and it's now 12.20. My timing is impeccable.
But looks like I may have made the right choice on selling SIGA when I did.
posted
Tough to find a floor of support to allow for a genuine short-term play on this stock, IMO. That's why I was wondering what everyone thought of the longer-term prospects for it, and a potential entry-point for a 2-3 month play.
-------------------- "Entrepreneurship is the last refuge of the trouble making individual."
Item 8.01. Other Events. On December 20, 2006, PharmAthene, Inc. ("PharmAthene") filed a complaint (the "Complaint") against SIGA Technologies, Inc. ("SIGA") in the Delaware Chancery Court. PharmAthene's complaint alleges that it has the right to license exclusively development and marketing rights for SIGA's drug candidate, SIGA-246, pursuant to, among other things, the recently terminated merger agreement between the parties. PharmAthene's complaint further alleges that SIGA failed to negotiate the terms of such license in good faith and otherwise failed to grant such license, and it seeks to compel SIGA to enter into such license and pay unspecified damages. SIGA believes that the complaint lacks merit and intends to contest vigorously the alleged claims.
-------------------- "Great Day for Up!"....Dr. Seuss
IP: Logged |
posted
SIGA: Successful Teatment of Child w/Lead Smallpox Drug Candidate 09:28 a.m. 03/19/2007 Provided by
Ridgeland, MS, MAR 19, 2007 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes*knobias.com
SIGA Technologies, Inc. (SIGA) announced that a toddler who inadvertently contracted eczema vaccinatum has been treated with ST-246, SIGA's lead smallpox drug candidate, pursuant to an Emergency Investigational New Drug Application (IND) granted by the FDA, and is now improving.
Due to the absence of smallpox disease in the general human population, the efficacy of ST-246 has been investigated in animals to date. However, the federal Centers for Disease Control and Prevention (CDC) was recently notified that a child had contracted eczema vaccinatum, a potentially deadly illness that can manifest with a generalized skin rash similar to smallpox, following accidental contact with an open skin lesion on a relative who had recently been vaccinated for smallpox using a live vaccinia virus vaccine. The patient developed late-stage manifestations of the disease, including hemorrhagic lesions, respiratory failure, shock and high viral loads in the blood. CDC facilitated communication between SIGA and FDA resulting in provision of ST-246 for the patient under an Emergency IND.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
posted
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 Tuesday May 15, 8:30 am ET
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193. ADVERTISEMENT
This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule."
"This is a tremendous milestone for our research group," said Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer. "This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future."
Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenaviruses are classified as Category A pathogens by the Centers for Disease Control and Prevention (CDC) due to the great risk that they pose to public health and national safety. Lassa fever is both a current world health threat, as it is prevalent in parts of West Africa (the CDC reports estimates of as many as 300,000 new cases each year), and a bioterror threat, due to its previous history as an object of weaponization research. Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. These include fever, retrosternal pain (pain behind the chest wall), sore throat, back pain, cough, abdominal pain, vomiting, diarrhea, conjunctivitis, facial swelling, proteinuria (protein in the urine), and mucosal bleeding. Neurological problems have also been described, including hearing loss, tremors, and encephalitis.
The Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats released in April by the Department of Health and Human Services lists arenaviruses as one of the biologic threats for which they plan to purchase medical countermeasures.
Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA, adds, "Progress on our Lassa fever virus drug demonstrates the robustness of our product pipeline and furthers our goal to develop safe and effective countermeasures against all of the Category A viral pathogens."
Development of this Lassa antiviral is supported by the National Institutes of Health (NIH), which awarded SIGA a $6.0 million grant in September 2006.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.
About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.
Forward-looking Statements
This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products, and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, are set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
Contact: SIGA Technologies, Inc. Dr. Eric A. Rose, 212-672-9100 Chairman and Chief Executive Officer info*siga.com or Cameron Associates Al Palombo, 212-245-8800 Ext. 209 Investor Relations al*cameronassoc.com
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Mad]](mad.gif)
